Antithrombotics Product description The Competitive Intelligence Report Antithrombotics as of August 2008 provides a competitor analysis in the development pipeline of novel anticoagulants and antiplatelet agents for prophylaxis and treatment of venous and arterial thromboembolic diseases. The report includes 2007 sales figures of the major products for low-molecular weight heparins (LMWH), specific indirect F. Xa inhibitor, direct thrombin inhibitors, antithrombin III, activated protein C (aPC) and inhibitors of platelet aggregation via the ADP receptor, glycoprotein IIb/IIIa (GP IIb/IIIa) or other mechanisms. The report provides a compilation of the active R&D projects in the field of new anticoagulants and new antiplatelet agents and of novel antithrombotic targets. Anticoagulants are presented separately for antithrombin agonists including novel drug delivery technologies, direct inhibitors of thrombin, selective indirect and direct inhibitors of Factor Xa (F. Xa), dual inhibitors targeting at both thrombin (F. IIa) and F. Xa and for inhibitors of other coagulation factors such as tissue factor (TF) / F. VIIa, F: VIII, F. IX and F. XI as well as of new inhibitors of the synthesis of coagulation factors. Antiplatelet agents in development are listed for those targeting the platelet ADP receptor and the protease-activated receptor-1 (PAR-1) / thrombin receptor as well as for antagonists of GP IIb/IIIa alone or as dual antagonists including a second target. Futhermore, novel antagonists of von Willebrand Factor (vWF) / GP Ib or GP VI are presented and pipeline compounds directed against other targets identified (thromboxane As, cyclooxygenase, integrins, serotonin 5-HT2A and others). In addition, novel antithrombotic targets such as the (thrombin-activatable fibrinolysis inhibitor) TAFIa, plasminogen activator inhibitor-1 (PAI-1) and others were found. The Competitor Analysis Antithrombotics also provides the Thrombosis R&D pipelines of major players form Big Pharma and specialty biotech companies. The report includes a compilation of current active projects in research and development of novel antihypertensives. Competitor projects are listed in a tabular format providing Information on: - Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index Antithrombotic Market: - 2007 Sales Figures for Selected Anticoagulants
- 2007 Sales Figures for Selected Antiplatelets
Anticoagulants: - Anti-Thrombin III Agonists
- Inhibitors of Thrombin (F. IIa)
- Indirect Inhibitors of F. Xa
- Direct Inhibitors of F. Xa
- Dual Inhibitors of F. Xa and F. IIa
- Other Coagulation Factor Inhibitors (IXa, TF/F. VIIa, F. VIII, F. XIa)
Antiplatelet Agents: - Inhibitors of Platelet ADP Receptor
- Inhibitors of PAR-1 / Thrombin Receptor
- Antagonists of GP IIb/IIIa
- Dual Antagonists of GP IIb/IIIa and 2nd Target
- Antagonists of von Willebrand Factor / GPIb
- Antagonists of GP VI
- Other Antiplatelet Targets (TXA2, COX, Integrins, 5-HT2A, Novel)
Novel Antithrombotic Targets: - TAFIa Inhibitors
- PAI-1 Inhibitors
- Other Novel Antithrombotic Targets
Selected Company R&D Pipelines: - AstraZeneca
- Bayer Schering Pharma
- Boehringer Ingelheim
- Daiichi Sankyo
- Endotis Pharma
- Nuvelo & Archemix
- Pfizer
- Portola Pharmaceuticals
- Sanofi-Aventis
- Schering-Plough
- The Medicines Company
- Trigen
- Wyeth
About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are independently elaborated by analysts of La Merie Business Intelligence and distributed by PipelineReview.com.
|
